Endologix to Present at Canaccord Genuity 34th Annual Growth Conference


IRVINE, Calif., Aug. 5, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chairman and Chief Executive Officer, is scheduled to present at the Canaccord Genuity 34th Annual Growth Conference in Boston, MA.

Event: Canaccord Genuity 34th Annual Growth Conference
Date: Thursday, August 14, 2014
Time: 8:30 a.m. ET / 5:30 a.m. PT

An audio webcast of the presentation will be available by visiting the investor relations section of Endologix's website at www.endologix.com. A replay of the presentation will be available for 30 days.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. Endologix focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com.



            

Contact Data